Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.95 CHF | +0.23% | +7.64% | +21.67% |
May. 03 | Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024 | CI |
Apr. 09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.67% | 570M | |
+17.96% | 47.02B | |
+48.77% | 41.86B | |
+1.17% | 41.76B | |
-4.27% | 28.8B | |
+11.42% | 26.05B | |
-21.39% | 19.15B | |
+4.86% | 12.55B | |
+27.29% | 12.34B | |
-3.50% | 11.82B |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Transcript : Basilea Pharmaceutica AG, H1 2022 Earnings Call, Aug 16, 2022